Anti-CD25 antibody (daclizumab) maintenance therapy in pancreas transplantation (Q46393235)

21 December 2017

title

Anti-CD25 antibody (daclizumab) maintenance therapy in pancreas transplantation (English)

1 reference

21 December 2017

0 references

5

1 reference

21 December 2017

author name string

V A Kirchner

1

1 reference

21 December 2017

T M Suszynski

2

1 reference

21 December 2017

D M Radosevich

3

1 reference

21 December 2017

A Humar

4

1 reference

21 December 2017

M J Hill

6

1 reference

21 December 2017

E B Finger

7

1 reference

21 December 2017

D E R Sutherland

8

1 reference

21 December 2017

R Kandaswamy

9

1 reference

21 December 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

21 December 2017

Transplantation Proceedings

published in

1 reference

21 December 2017

volume

42

1 reference

21 December 2017

issue

6

1 reference

21 December 2017

page(s)

2003-2005

1 reference

21 December 2017

Advances in immunosuppression for pancreas transplantation

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.05.083

Late-onset tacrolimus-associated cerebellar atrophia in a heart transplant recipient.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.05.083

Chronic renal failure after transplantation of a nonrenal organ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.05.083

Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.05.083

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.05.083

Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.05.083

Immunosuppression with low-dose daclizumab in liver transplant recipients with impaired kidney function: a single-center experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.05.083

Extended daclizumab monotherapy for rejection-free survival in non-adherent adolescent recipients of renal allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.05.083

Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.05.083

Use of low dose tacrolimus, mycophenolate mofetil and maintenance IL-2 receptor blockade in an islet transplant recipient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.05.083

Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.05.083

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.05.083

Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.05.083

Mechanism of FK506-induced glucose intolerance in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.05.083

Tacrolimus impairment of insulin secretion in isolated rat islets occurs at multiple distal sites in stimulus-secretion coupling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.05.083

Tacrolimus and sirolimus cause insulin resistance in normal sprague dawley rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.05.083

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.05.083

10.1016/J.TRANSPROCEED.2010.05.083

7 January 2021

Identifiers

DOI

1 reference

21 December 2017

1 reference

21 December 2017